PM Modi announces USD 200 mn line of credit for Kyrgyzstan as two sides sign 15 pacts
Bishkek, Jun 14: Prime Minister Narendra Modi on Friday announced a USD 200 million line of credit for Kyrgyzstan after wide-ranging talks with Kyrgyz President Sooronbay Jeenbekov as the two sides upgraded their ties to the strategic partnership level and signed 15 agreements, including one to eliminate double taxation.
Prime Minister Modi and President Jeenbekov held one-on-one restricted meeting followed by a delegation-level talks during which the two sides discussed on stepping up their bilateral engagement to the next level and exploring new areas of cooperation.
Later at a joint press statement, Modi announced the USD 200 million line of credit for Kyrgyzstan and said the two sides have decided to upgrade their ties to the Strategic Partnership level.
Prime Minister Modi also said that the two sides have prepared a five-year road map to increase the bilateral trade.
He said that the two countries share views on several issues and they have signed 15 agreements, including on the Double Taxation Avoidance Agreement (DTAA).
They also signed the Bilateral Investment Treaty (BIT), MoUs in the field of Health, security, defence and Information and Communication Technology.
Prime Minister Modi emphasised on the counter terror cooperation between the two sides and said terrorism cannot be justified in any manner.
"We are together in fight against terrorism, it is imperative to give out a message to the world that terrorism will not be tolerated at any cost," he said.
Earlier, Prime Minister Modi was accorded a red carpet welcome at the Ala Archa Presidential Palace here.
"India & Kyrgyzstan are now strategic partners! In a major outcome of the visit, both countries have decided to add strategic dimension to our ties to boost our relationship in defence & security, trade & investment, health, education & development cooperation, among other areas," External Affairs Ministry spokesperson Raveesh Kumar tweeted after the talks between the two leaders.
Modi arrived in the Kyrgyz capital on Thursday for the two-day Shanghai Cooperation Organisation (SCO) Summit. The SCO is a China-led 8-member economic and security bloc with India and Pakistan being admitted to the grouping in 2017.
Let the Truth be known. If you read VB and like VB, please be a VB Supporter and Help us deliver the Truth to one and all.
Jamia prof receives Rs 94 lakh grant to formulate AI-driven drug to treat breast cancer
New Delhi (PTI): An associate professor at Jamia Millia Islamia has been awarded a research grant of approximately Rs 94 lakh by the prestigious ICMR to support research in leveraging Artificial Intelligence for treatment of breast cancer.
The Indian Council of Medical Research (ICMR) has granted funding to Raza to develop cutting-edge tools for AI-guided drug design, focusing on optimising drug compounds, identifying therapeutic targets, and formulating novel treatment strategies for breast cancer, a statement by the varsity said on Friday.
One such promising drug compound 'DdpMPyPEPhU' already patented by Raza will be further explored under this initiative, the statement said.
This research will address critical challenges in breast cancer treatment and is expected to yield transformative outcomes that could impact healthcare practices globally, it added.
The three-year funding will facilitate advanced experimentation, foster collaboration with leading experts, and accelerate the development of innovative solutions for breast cancer treatment.
Jamia Vice-Chancellor Mazhar Asif and Registrar Md. Mahtab Alam Rizvi congratulated Raza on this accomplishment.
Asif stated, “This is a moment of immense pride for JMI. Raza’s recognition by ICMR underscores the university’s commitment to fostering research excellence and innovation. His groundbreaking work showcases JMI’s vital contributions to integrating AI in healthcare research.”
Expressing gratitude for the recognition, Raza said, “I am deeply honoured to receive this grant from ICMR. It represents a tremendous opportunity to advance our research on AI- driven drug design and contribute to better health outcomes for millions. I am thankful to my research team, collaborators and ICMR for their unwavering support.”
Raza is known for his research in the application of AI in healthcare, focusing on designing and optimising drug compounds through AI-based multitarget docking, molecular simulations, and genomics-driven personalised medicine.
